On August 20, 2019 GT Biopharma, Inc. (OTCQB:GTBP) (GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company’s proprietary NK cell engager (TriKE) platform and Multi-Target Directed Bispecific Drug Conjugate platform, reported that Jeffrey Miller, M.D. has been hired by the Company as its Consulting Chief Medical Officer (Press release, GT Biopharma , AUG 20, 2019, View Source [SID1234539510]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Miller is currently Professor of Medicine at the University of Minnesota, and is the Deputy Director of the University of Minnesota’s Masonic Comprehensive Cancer Center. Dr. Miller has more than 20 years of experience studying the biology of NK cells, and other immune effector cells and their use in clinical immunotherapy with over 170 peer-reviewed publications. Dr. Miller is a board certified physician specializing in hematological oncology. Dr. Miller is a member of numerous societies such as the American Society of Hematology (ASH) (Free ASH Whitepaper), the American Association of Immunologists, and has been a member of the American Society of Clinical Investigation since 1999. Dr. Miller serves on the editorial board for Blood, and is a reviewer for a number of journals and NIH grants.
Mr. Anthony Cataldo, the Chairman and Chief Executive Officer of GT Biopharma commented "we are pleased Jeff has agreed to become our Consulting Chief Medical Officer". Mr. Cataldo further stated "Jeff is an outstanding physician and scientist, and is the inventor of our highly sought after TriKE platform technology".
About GTB-3550 Trispecific NK cell Engager (TriKE)
GTB-3550 (OXS-3550) is the Company’s first Tri-specific NK cell Engager (TriKE) product candidate being initially developed for the treatment AML. GTB-3550 is a single-chain, tri-specific scFv recombinant fusion protein conjugate composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The natural killer (NK) cell stimulating cytokine human IL-15 portion of the molecule provides a self-sustaining signal that activates NK cells and enhances their ability to kill. We intend to study GTB-3550 in CD33 positive leukemias such as acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other CD33+ hematopoietic malignancies.
About GTB-1550 Multi-Target Directed Bispecific Drug Conjugate
GTB-1550 targets cancer cells expressing the CD19 receptor or CD22 receptor or both receptors thereby maximizing cancer cell recognition by binding to CD19+, CD22+ and CD19+/CD22+ cancer cells. When GTB-1550 binds to cancer cells, the cancer cells internalize GTB-1550, and are killed due to the action of drug’s cytotoxic diphtheria toxin payload.